scholarly journals A complicated case of pulmonary embolism in a patient with renal failure

2015 ◽  
Vol 4 (3S) ◽  
pp. 47-54
Author(s):  
Fulvio Pomero ◽  
Chiara Brignone ◽  
Giovanni Gollè ◽  
Alberto Silvestri ◽  
Elena Migliore ◽  
...  

We describe a case of pulmonary embolism with instable hemodynamics in a patient with renal failure; the case is complicated by heparin-induced thrombocytopenia (HIT). Renal failure has a high prevalence in hospitalized patients and is a restriction on administration of low molecular weight heparins (LMWH) and fondaparinux. HIT is a potentially life-threatening complication, therefore a precocious diagnosis is essential. Therapy consists in the immediate stop of heparin’s administration and in the administration of non-heparin antithrombotic drugs.

Author(s):  
Gunduz T ◽  
Cakir M ◽  
Bakirci EM ◽  
DEGIRMENCI H

Heparin-İnduced Thrombocytopenia (HIT) is a life-threatening complication that occurs in a small percentage of exposed patients (e.g. unfractionated heparin, Low Molecular Weight Heparin [LMWH]) regardless of dose and treatment management.


Author(s):  
Fernando Scudiero ◽  
Antonino Pitì ◽  
Roberto Keim ◽  
Guido Parodi

Abstract Background Despite the fast-growing understanding of the coronavirus disease 2019 (COVID-19), patient management remains largely empirical or based on retrospective studies. In this complex scenario, an important clinical issue appears to be represented by the high prevalence of thromboembolic events, but the data regarding high-risk pulmonary embolism (PE) is still not available. Case summary A patient with COVID-19 developed sudden shortness of breath and hypoxia. Early echocardiographic diagnosis of high-risk PE related to right heart thrombus was performed. Systemic thrombolysis was administered with excellent clinical and haemodynamic response. Discussion Pulmonary thromboembolism is a common occurrence in severe COVID-19 infection. In our experience, systemic thrombolysis proved to be effective and for this reason may be considered for life-threatening PE in COVID-19 patients.


Author(s):  
Syahfori Widiyani ◽  
Irsalina Rahmawati ◽  
W. Yohannes Widodo ◽  
Dian Zamroni ◽  
Fajar L. Gultom ◽  
...  

Introduction: Bullous haemorrhagic dermatosis is a rare clinical disorder which is usually related to a treatment with unfractionated heparin (UFH) or low molecular weight heparin (LMWH), characterized by multiple intra-epidermal haemorrhages distant from the site of injection. Presentation of Case: A 62-year-old male patient with coronary heart disease who received heparin treatment experienced several tense, haemorrhagic bullae located on the right arm area, close to the injection site, and followed by the formation of several hematomas on his back trunk 2 days after he had received UFH. The lesions regressed after discontinuation of heparin and supportive topical treatments. Discussion: The lesions in this patient have similar characteristic with heparin-induced skin necrosis and demonstrate thrombocytopenia probably related to heparin. There are some proposed hypotheses of pathophysiology which include hypersensitivity reaction and idiosyncratic dose-related reaction. Given the clinically course, the discontinuation of heparin treatment was essential for lesion regression in addition other supportive measures. Conclusion: Heparin-induced skin lesions may indicate the presence of life-threatening heparin-induced thrombocytopenia. An early diagnosis is crucial to enable discontinuation of heparin if required.


2020 ◽  
Vol 2020 ◽  
pp. 1-3
Author(s):  
Haneen Abdalhadi ◽  
Yazan Fahmawi ◽  
Abhijin Das ◽  
Brian Fouty

Thrombocytopenia is a rare and sometimes life-threatening complication of Vancomycin. A 52-year-old male patient with acute kidney injury was treated with Vancomycin for ventilator-associated pneumonia. Three days later, his platelets decreased from 172×109/L to 3×109/L over a 36-hour period. The patient developed significant intrapulmonary bleeding leading to profound hypoxemia. Workup was negative for thrombotic thrombocytopenic purpura, disseminated intravascular coagulopathy, atypical hemolytic uremic syndrome, heparin-induced thrombocytopenia, and autoimmune diseases. All recently started medications were discontinued, and the patient was started empirically on methylprednisolone and intravenous immunoglobulin. The patient’s platelets increased, and his airway bleeding stopped within 48 hours; his platelet count returned to normal by 18 days. Vancomycin-dependent anti-platelet antibodies were identified in the patient’s serum by flow cytometry. Thrombocytopenia is an underrecognized complication of Vancomycin that can lead to life-threating bleeding. Stopping Vancomycin may be sufficient to reverse the thrombocytopenia in patients with normal renal function, but more aggressive measures such as steroids, IVIG, and dialysis may be required to stop bleeding and reverse thrombocytopenia in patients with underlying kidney injury who cannot effectively excrete Vancomycin.


1998 ◽  
Vol 80 (08) ◽  
pp. 292-297 ◽  
Author(s):  
Peter Newman ◽  
Rebecca Swanson ◽  
Beng Chong

SummaryEarly diagnosis of heparin-induced thrombocytopenia (HIT) is essential to reduce morbidity and mortality. We report an enzyme immunoassay which detects the binding of HIT IgG to PF4-heparin in the fluid phase. Our fluid phase assay produces consistently low background and can detect low levels of anti-PF4-heparin. It is suited to testing alternative anticoagulants because, unlike in an ELISA, a clearly defined amount of antigen is available for antibody binding. We were able to detect anti-PF4-heparin IgG in 26/28 (93%) HIT patients. We investigated cross-reactivity of anti-PF4-heparin antibodies with PF4 complexed to alternative heparin-like anticoagulants. Low molecular weight heparins cross-reacted with 23/26 (88%) of the sera from HIT patients while half of the HIT sera weakly cross-reacted with PF4-danaparoid (Orgaran). The thrombocytopenia and thrombosis of most of these patients resolved during danaparoid therapy, indicating that detection of low affinity antibodies to PF4-danaparoid by immunoassay may not be an absolute contraindication for danaparoid administration.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 1244-1244
Author(s):  
Kirsty M Cuthill ◽  
Andrew Retter ◽  
David A Gurney ◽  
Gary W Moore

Abstract Background: Heparin induced thrombocytopenia (HIT) is a prothrombotic adverse drug reaction to heparin. The 4T scoring system is a well validated system for assessing the pre-test probability of HIT and has a high negative predictive value for excluding HIT in most clinical situations, however, only a minority of patients have been evaluated in the ICU setting. The critically ill pose different challenges when compared with other medical and surgical patients. They have increased rates of thrombotic and haemorrhagic complications. Thrombocytopenia is reported in approximately 30–50%. We examined our ICU experience to evaluate the pairing of the 4T scoring system and EIA-GTI PF4 ELISA assay to evaluate their diagnostic accuracy in confirming a diagnosis of HIT in the acute setting. The gold standard measure is the serotonin release assay (SRA), but this is not routinely available in the UK. Methods: This single centre, retrospective, observational study involved reviewing the records of 75 consecutive patients investigated for HIT on our ICU from February 2006 to April 2008. We follow the British Society of Haematology guidelines for the management of HIT. Initial testing is with the EIA-GTI PF4 assay (positive if >0.4 OD) coupled with a heparin induced platelet activation assay (HIPA). Results: During the 26 months studied, 3.5% of ICU admissions were screened for HIT. A diagnosis of HIT, defined in this study as an intermediate or high 4T pre-test probability score and an ELISA result >0.7 OD was present in 0.46%. 45% of patients were medical, 40% had cardiothoracic surgery, the remaining 15% were general surgical patients. 66% had three or more organ failure, 70% received haemofiltration. Severe sepsis and haemofiltration were alternative causes of thrombocytopenia in 97% of patients. The 4T’s were used to risk stratify patients, 68% of patients had a low score, 29% were at intermediate risk and 3% had a high probability of HIT. 76% of patients with a low pre test probability had a negative ELISA and none developed a thrombosis. 4 (8%) patients with a low pre-test probability had a positive ELISA with an optical density >0.7 OD. 4 patients had a low pre-test probability but a positive ELISA, none of whom developed a thrombus. 2 patients had a positive ELISA and a positive HIPA, both had an intermediate pre-test probability. 1 patient had a negative ELISA (<0.4 OD) in the context of a high pre-test probability, he became thrombocytopenic on repeated heparin exposure. There was no correlation between a high pre-test probability and the magnitude of the ELISA result. 10 patients were treated with lepirudin, 2 developed haemorrhage requiring interruption of anticoagulation and transfusion. Discussion: The incidence of HIT recorded over the 26 month study period at GSTT is similar to the incidence of 0.3 -0.5% reported by Selleng. No diagnoses of HIT were missed after increasing our ELISA threshold from 0.4 - 0.7 OD. Neither the 4T pre-test probability nor the EIA GTI PF4 ELISA alone are sufficient to exclude a diagnosis of HIT. The 4T scoring system although well validated system may not work as well in the critically ill. The high prevalence of thrombocytopenia and alternative causes of thrombocytopenia mean the presence of thrombosis and the timing of the thrombocytopenia post heparin exposure are the major discerning features. Lo has previously reported the potential to over diagnose HIT by 100% when using the EIAGTI ELISA (Lo GK. Am J Hematol.2007; 82: 1037–43). The positive ELISA results in those patients with a low pre-test probability may be false positives secondary to cross-reacting autoantibodies. The high prevalence of acute renal failure highlights the importance of making an accurate diagnosis of HIT. Use of lepirudin in renal failure is associated with an increased risk of haemorrhage. We use 10% of the standard dose in patients with renal failure, haemorrhage occurred despite intensive monitoring in 20% of the patients. Our study is limited by its retrospective design and the lack of SRA testing. We recommend that both tests are performed in patients at risk of HIT. Increasing the positive ELISA threshold to 0.7 OD improves the specificity of the ELISA for detecting clinically significant heparin/PF4 antibodies in critically ill patients.


2013 ◽  
Vol 2013 ◽  
pp. 1-3 ◽  
Author(s):  
Thomas Godet ◽  
Sébastien Perbet ◽  
Aurélien Lebreton ◽  
Guillaume Gayraud ◽  
Sophie Cayot ◽  
...  

Low molecular weight heparins (LMWH) are commonly used in the ICU setting for thromboprophylaxis as well as curative decoagulation as required during renal replacement therapy (RRT). A rare adverse event revealing immunoallergic LMWH induced thrombopenia (HIT) is skin necrosis at injection sites. We report the case of a patient presenting with skin necrosis witnessing an HIT after RRT, without thrombocytopenia. The mechanism remains unclear. Anti-PF4/heparin antibodies, functional tests (HIPA and/or SRA), and skin biopsy are of great help to evaluate differential diagnosis with a low pretest probability 4T’s score.


Sign in / Sign up

Export Citation Format

Share Document